Harnessing the power of immune cells, especially T cells, to enhance anti-tumor activities
has become a promising strategy in clinical management of hematologic malignancies. The …

Progress in the research and therapy of adult acute lymphoblastic leukemia (ALL) is
accelerating. This analysis summarizes the data derived from the clinical trials conducted at …

Purpose Few therapeutic options are available for patients with Philadelphia chromosome–
positive (Ph+) B-precursor acute lymphoblastic leukemia (ALL) who progress after failure of …

Importance With the advent of potent BCR:: ABL1 tyrosine kinase inhibitors (TKIs),
Philadelphia chromosome-positive (Ph-positive) acute lymphoblastic leukemia (ALL) is now …

The estimated overall incidence of acute lymphoblastic leukaemia (ALL) and lymphoblastic
lymphoma in Europe is 1.28 per 100 000 individuals annually, with significant age-related …

Conventional cytotoxic chemotherapy used to treat acute lymphoblastic leukemia (ALL)
results in high cure rates in pediatric patients but is suboptimal in the treatment of adult …

Recent years have witnessed major advances that have improved outcome of adults with
acute lymphoblastic leukemia (ALL). The emergence of the concept of measurable residual …

Genomic landscapes of 92 adult and 111 pediatric patients with B-cell acute lymphoblastic
leukemia (B-ALL) were investigated using next-generation sequencing and copy number …

Abstract Prognosis of Philadelphia-positive (Ph+) acute lymphoblastic leukemia (ALL) in the
elderly has improved during the imatinib era. We investigated dasatinib, another potent …

The combination of ponatinib, a third‐generation BCR:: ABL1 tyrosine kinase inhibitor, with
hyper‐CVAD chemotherapy resulted in high rates of complete molecular remissions and …